Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. TaiGen Biopharmaceuticals Holdings's Revenue for the
three
months ended in Mar. 2026 was NT$10.3 Mil. TaiGen Biopharmaceuticals Holdings's average Accounts Receivable for the
three
months ended in Mar. 2026 was NT$4.7 Mil.
Hence, TaiGen Biopharmaceuticals Holdings's Receivables Turnover for the
three
months ended in Mar. 2026 was 2.19.
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
TaiGen Biopharmaceuticals Holdings Receivables Turnover Related Terms
TaiGen Biopharmaceuticals Holdings Receivables Turnover Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:4157 vs VRTX, REGN, RVMD: Receivables Turnover Comparison
For the Biotechnology subindustry, TaiGen Biopharmaceuticals Holdings's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
TaiGen Biopharmaceuticals Holdings Receivables Turnover vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, TaiGen Biopharmaceuticals Holdings's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where TaiGen Biopharmaceuticals Holdings's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TaiGen Biopharmaceuticals Holdings (ROCO:4157) has a Receivables Turnover of 2.19 as of Mar. 2026. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on TaiGen Biopharmaceuticals Holdings and its competitors. According to the industry distribution chart, TaiGen Biopharmaceuticals Holdings ranks #42 out of 843 companies in the Biotechnology industry, placing it in the top 5%.
Is TaiGen Biopharmaceuticals Holdings' Receivables Turnover too high?
TaiGen Biopharmaceuticals Holdings' current Receivables Turnover is 2.19. The Biotechnology industry median Receivables Turnover is 5.27. TaiGen Biopharmaceuticals Holdings' value of 2.19 is 58.4% below this industry median. Based on the distribution chart, TaiGen Biopharmaceuticals Holdings ranks #42 out of 843 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, TaiGen Biopharmaceuticals Holdings has a GF Score™ of 58/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does TaiGen Biopharmaceuticals Holdings' Receivables Turnover compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, TaiGen Biopharmaceuticals Holdings ranks #42 out of 843 companies for Receivables Turnover. This places TaiGen Biopharmaceuticals Holdings in the top 5% of its industry — outperforming the majority of peers. The industry median Receivables Turnover is 5.27. TaiGen Biopharmaceuticals Holdings' value of 2.19 is 58.4% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Biotechnology company?
The median Receivables Turnover among Biotechnology companies is 5.27, based on 843 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. TaiGen Biopharmaceuticals Holdings's current Receivables Turnover of 2.19 is 58.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on TaiGen Biopharmaceuticals Holdings and its competitors. For the Biotechnology industry, the median Receivables Turnover is 5.27 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. TaiGen Biopharmaceuticals Holdings's current Receivables Turnover is 2.19. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TaiGen Biopharmaceuticals Holdings stock overvalued right now?
Based on GuruFocus' analysis, TaiGen Biopharmaceuticals Holdings (ROCO:4157) is currently considered Significantly Undervalued. The stock's GF Value™ is NT$31.02, compared to a current price of NT$9.06 — trading 70.8% below its estimated fair value. The current Receivables Turnover is 2.19 and 58.4% below the Biotechnology industry median of 5.27. TaiGen Biopharmaceuticals Holdings' overall GF Score™ is 58/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For TaiGen Biopharmaceuticals Holdings (ROCO:4157), the current Receivables Turnover is 2.19 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is TaiGen Biopharmaceuticals Holdings (ROCO:4157) Overvalued in 2026?
Based on GuruFocus' analysis, TaiGen Biopharmaceuticals Holdings stock appears to be undervalued.
The current stock price of NT$9.06 is trading 70.8% below its estimated GF Value™ of NT$31.02.
GuruFocus considers TaiGen Biopharmaceuticals Holdings to be Significantly Undervalued.
Key valuation signals for ROCO:4157:
Receivables Turnover: 2.19
GF Value™: NT$31.02 vs. price of NT$9.06 (70.8% below fair value)
Industry Position: 58.4% below the Biotechnology median (#42 of 843)
No single metric tells the full story. See the ROCO:4157 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
TaiGen Biopharmaceuticals Holdings Ltd is mainly engaged in the research and development of new drugs, including the selection of drug candidates, pre-IND trials and clinical trials. Its operating segment includes development, research and sales of new drugs, and other. The majority of the revenue is generated from development, research and sales of new drugs.
58GF Score
Get the complete analysis for ROCO:4157
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:4157 has been successfully added to your 
